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Abstract
 
During an immune response naive T helper (Th) cells differentiate into two functionally dis-
tinct subsets, Th1 and Th2, based on their cytokine secretion profile and immunomodulatory
function. c-Jun amino terminal kinase (JNK) regulates Th cell differentiation by activating a
transcriptional program required for cytokine production. We have recently identified a
TNFR superfamily death domain–containing molecule, death receptor (DR)6, which potently
activates JNK. T cells from DR6-deficient mice are substantially impaired in JNK activation.
 
When DR6
 
 
 
/
 
 
 
 mice were challenged with protein antigen, their T cells hyperproliferate and
display a profound polarization toward a Th2 response whereas Th1 differentiation is not
equivalently affected. In addition, DR6
 
 
 
/
 
 
 
 
 
T cells showed preference toward Th2 differentia-
tion in vitro. The phenotype seen in the DR6
 
 
 
/
 
 
 
 mice is not due to the apoptotic pathway.
Therefore, DR6, working through JNK, rather than apoptosis, functions to attenuate the Th2
response. This is the first demonstration of a role in the activation and differentiation of Th
cells by DR6 in particular and DRs in general.
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Introduction
 
When activated by APCs, naive CD4
 
 
 
 Th cells undergo
clonal expansion and secrete IL-2 (1). After 4–5 d of prolif-
eration, a significant reprogramming of gene expression oc-
curs that is mediated by the cytokine microenvironment,
allowing for the emergence of predominantly Th1 or Th2
cell populations (2–6). Th1 cells are responsible for cell-
mediated inflammatory reactions as they secrete cytokines
such as IFN-
 
 
 
 and TNF-
 
  
 
(3, 7). In contrast, Th2 cells
mediate B cell activation and differentiation by virtue of se-
creting IL-4, IL-5, IL-9, IL-10, and IL-13, all of which
promote humoral immunity (2, 8). An intracellular signal-
ing pathway that regulates Th cell differentiation has re-
cently been found to involve c-Jun amino terminal kinase
 
(JNK)
 
*
 
-1, a MAP kinase that phosphorylates and activates a
number of transcription factors including c-Jun, Jun D,
Elk-1, ATF, and Sap-1 (9–11). The most direct proof for
the involvement of JNK-1 in the balance of Th1 and Th2
immune responses comes from the study of JNK-1 null
mice (12). After keyhole limpet haemocyanin (KLH) im-
munization, JNK-1–deficient mice display an enhanced
Th2 type cytokine response, suggesting that JNK-1 nor-
mally functions to suppress the production of Th2 type cy-
tokines. Signals from both the TCR–CD3 complex and
costimulatory receptors such as CD28 are required for JNK
activation (12). Our studies suggest that death receptor
(DR)6 fulfills an important costimulatory role for JNK-1
activation in T cells.
Many members of the TNF ligand superfamily and their
cognate receptors play a critical role in organogenesis of
lymphoid organs and homeostatic regulation of immune
effector cells (13). DR6 was identified as a member of the
TNFR family based on the presence of characteristic extra-
cellular cysteine-rich domains. These 40 amino acid pseu-
dorepeats typically consist of six highly conserved cysteines.
The cytoplasmic domains of TNFR are less well conserved
with the exception of death domains (DDs) that are present
in a subset of receptors termed DRs, including TNFR1,
CD95, EDAR, DR3, DR4, DR5, and DR6 (14–20). The
 
DD is typically composed of 
 
 
 
60 amino acids forming a
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globular structure of six conserved 
 
 
 
 helices with a charac-
teristic “greek key” topology. Upon ligand engagement,
one major signaling event for DRs is the recruitment of
DD-containing adaptors through homotypic association. In
contrast to most DD-containing receptors in the family,
even upon overexpression, DR6 does not induce cell death
in the apoptosis sensitive indicator cell line, MCF-7, sug-
gesting an alternate function. Consistent with this, DR6
does not convincingly associate with DD-containing adap-
tor molecules including TRADD, FADD, RAIDD, and
RIP that mediate downstream signaling from activated
DRs (21). Regardless, upon overexpression, which for
TNFR family members mimics ligand activation, DR6 was
found to be a potent inducer of JNK activation.
Activation of the JNK pathway and DR6’s expression in
lymphoid organs such as thymus, spleen and lymphoid cells
(21), suggested a possible role for DR6 in immune func-
tion. To explore this possibility we generated DR6-defi-
cient mice. When these mice were challenged with protein
antigen, their T cells hyperproliferated, and DR6
 
 
 
/
 
 
 
 T cells
showed preference toward Th2 differentiation in vitro. Al-
though the DR6 is a DD-containing receptor, the DR6
null mutation had no effect on apoptosis; the phenotype
seen in the DR6
 
 
 
/
 
  
 
mice was independent of apoptosis.
These results support the notion that DR6, working
through JNK regulates the differentiation of Th cells.
 
Materials and Methods
 
Generation of DR6-deficient Mice.
 
The targeting construct
containing 12.8 kb of 5
 
 
 
 homology and 4.0 kb of 3
 
 
 
 homology
was linearized and used to electroporate 10
 
7
 
 ES cells. After posi-
tive/negative selection with G418 and gancyclovir, surviving ES
clones were screened for homologous recombination by South-
ern blot analysis. Genomic DNA was digested with Sac1 and hy-
bridized with a 241-bp probe from a region just upstream to the
1.8-kb homology arm. Targeted ES clones were used to generate
chimeric animals by injection into C57BL/6 blastocysts. Male
chimeras were bred with C57BL/6 females and tail biopsies of
agouti-colored offspring screened to identify germline transmis-
sion. Heterozygous mice were interbred to generate DR6-defi-
cient animals. Expression of DR6 gene was evaluated by reverse
transcription (RT)-PCR analysis using total RNA isolated
from livers and a custom pair of forward (5
 
 
 
GGCATCGAG-
GAAGGGACAGTG3
 
 
 
) and reverse primers (5
 
 
 
TTGATGT-
CGAAATGCTTGTGAGC3
 
 
 
).
 
Taqman™ PCR.
 
Quantitative RT-PCR was performed us-
ing Taqman™ assay reagents (Applied Biosystems). Total RNA
was extracted using QIAGEN RNeasy columns and digested
with DNase 1 to remove contaminating genomic DNA. All Taq-
man™ reactions were performed in duplicate and normalized to
rpl19, a ribosomal housekeeping gene. Primer sequences used for
mouse DR6 Taqman™ analysis were: forward primer, 5
 
 
 
CAC-
CACGCAGTTGGAAAC3
 
 
 
, reverse primer, 5
 
 
 
GAATTCTC-
AAGTTTCACGTTAGGA3
 
 
 
 and probe primer, 5
 
 
 
ACTGGCT-
CTCCCCATGAGCCC 3
 
 
 
.
 
Flow Cytometry.
 
Single cell suspension from various tissues
was stained with conjugated mAbs (BD PharMingen) for 30 min
at 4
 
 
 
C. Fluorescence was analyzed using a FACScan™ instru-
ment and associated CELLQuest™ software (Becton Dickinson).
 
In Vitro T Cell Assays.
 
For polyclonal stimulation of T cells,
5 
 
 
 
 10
 
5
 
 purified CD4
 
 
 
 T cells were cultured in the presence of
different concentrations of Con A or anti-CD3 alone or in the
presence of anti-CD28 in 96-well plates in triplicate. Prolifera-
tion was measured by addition of 1 
 
 
 
Ci of [
 
3
 
H]thymidine (ICN
Biomedicals) for the last 18 h of a 5-d culture and incorporation
of radioactivity assayed by liquid scintillation counting.
 
In Vivo T Cell Activation.
 
For anti-KLH responses, mice
were immunized with 100 
 
 
 
g KLH in saline, in a 1:1 emulsion
with CFA (Difco Laboratories) in the hind footpads. After 9 d,
popliteal lymph nodes were removed and cell suspensions were
prepared. The recovered lymph node cells were cultured (5 
 
 
 
10
 
5
 
 cells per well) with indicated concentrations of KLH and pro-
liferation assessed by uptake of [
 
3
 
H]thymidine as described previ-
ously. Assays for cytokine production by T cells were conducted
by culturing 5 
 
 
 
 10
 
5
 
 draining lymph node cells either from
KLH-primed wild-type or DR6-deficient mice in the presence
of KLH in two sets of 96-well plates in triplicate at a final volume
of 200 
 
 
 
l. From one set of plates, after overnight culture, 150 
 
 
 
l of
culture supernatant was removed for determination of IL-2. From
the second set of plates, after 96 h of culture, 150 
 
 
 
l of culture
supernatant was removed for determination of IL-4 and IFN-
 
 
 
by ELISA using antibodies from BD PharMingen.
 
Serum Ig Concentrations.
 
Unimmunized mice were bled at 12
wk of age and serum was analyzed for various Ig isotypes by
ELISA using a kit from BD PharMingen.
 
Generation of Antigen-specific Antibodies.
 
For trinitrophenyl
(TNP)-specific antibodies, 5-wk-old wild-type or DR6-deficient
mice were immunized intraperitoneally with TNP-KLH in CFA
and 10 d later mice were bled and serum was analyzed for TNP-
specific antibodies using standard ELISA protocols.
 
In Vitro Differentiation of T Cells.
 
Naive T cells from the
spleen and lymph nodes of wild-type or DR6-deficient litter-
mates were purified using MACS
 
®
 
 CD4
 
 
 
 microbeads (Miltenyi
Biotec) according to the manufacturer’s instructions. Purified T
cells (10
 
6 
 
cells per milliliter) were cultured in the presence of
plastic-immobilized anti-CD3 (5 
 
 
 
g/ml) and anti-CD28 (1 
 
 
 
g/
ml) plus IL-12 (3.5 ng/ml; R & D Systems) and 500 ng/ml IL-4
antibody (BD PharMingen) to promote Th1 cell differentiation
or IL-4 (10
 
3 
 
U/ml; R & D Systems) and 500 ng/ml anti–IFN-
 
 
 
(BD PharMingen) for Th2 differentiation. After 4 d, cells were
exhaustively washed, counted, and restimulated at 10
 
6
 
 cells per
milliliter with plastic-immobilized anti-CD3 (5 
 
 
 
g/ml). Super-
natants were harvested 24 h later and analyzed for the presence
of cytokines.
 
Apoptosis Assays.
 
Thymocytes were resuspended at 5 
 
 
 
 10
 
6
 
cells per milliliter in high glucose DMEM containing 10% FCS
(complete medium [CM]) and plated in a final volume of 200 ul
in 96-well flat-bottomed tissue culture plates and the following
proapoptotic stimuli administered: medium alone; soluble FLAG-
tagged FasL and FLAG antibody at 1 ug/ml each; plate-bound
anti-CD3 and anti-CD28 (BD PharMingen) both at 20 ug/ml;
etoposide at 100 uM; dexamethasone (Sigma-Aldrich) at 2 uM.
24 h later, thymocytes were harvested, stained with annexin V
and propidium iodide, and analyzed by flow cytometry.
 
Measurement of Activation-induced Cell Death.
 
For activation-
induced cell death (AICD) in splenocytes, cells from wild-type
and DR6-deficient mice were isolated and washed twice in CM.
Cells were stimulated by the addition of ConA (5 
 
 
 
g/ml) and 50
U/ml of recombinant mouse IL-2 (100 IU/ml; Genzyme) for 48 h,
followed by culture in CM containing murine recombinant
IL-2  for 48 h. Cells were then Lympholyte-M purified and
washed twice in CM. The activated lymphocytes were treated 
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with either plate-bound 
 
 
 
-CD3 (5 
 
 
 
g/ml) or soluble FLAG-
tagged FasL and 
 
 
 
-FLAG M2 (Sigma-Aldrich) at 1 
 
 
 
g/ml each
for 24 h. Treated cells were harvested and percentage of cell
death determined using annexin V and PI staining of cells by
flow cytometry.
 
Measurement of JNK Activity in Splenocytes.
 
Purified splenic T
cells from wild-type or DR6-deficient mice were stimulated with
plate-bound anti-CD3 (5 
 
 
 
g/ml) and anti-CD28 (1 
 
 
 
g/ml) for
48 h. JNK activity was measured with JNK assay kit using GST-
Jun as substrate (New England Biolabs, Inc.).
 
Results
 
Cloning and Expression of DR6.
 
To investigate the
physiological function of DR6, a knockout strategy was
devised, the first step of which was cloning a murine
cDNA encoding DR6. Murine and human DR6 displayed
88% protein sequence identity (Fig. 1 A). Examination of
mouse tissues by Northern blot analysis demonstrated the
presence of a 4-kb DR6 transcript in adult lymphoid tissues
including PBLs, thymus, and spleen. The transcript could
also be detected at varying levels in every adult or fetal tis-
sue analyzed (Fig. 1 B). To further characterize the expres-
sion pattern of DR6 in various lymphoid cell populations,
we performed real time quantitative RT-PCR by Taq-
man™ assay using total RNA extracted from various cell
 
populations. Our analysis indicated that DR6 was present
on CD4
 
 
 
, CD8
 
 
 
, CD19
 
 
 
, and CD14
 
 
 
 cells, suggesting
that DR6 is specifically expressed on T cells, B cells, and
monocytes (data not shown). DR6 expression was also de-
termined in Th0 and differentiated Th1 and Th2 cells.
DR6 mRNA was found in Th0 cells as well as in Th1 and
Th2 cells; however, levels of DR6 transcript were twofold
higher in Th2 cells (Fig. 1 C). These results reinforced the
notion that DR6 may be important in immune function
and potentially regulate Th cell responses.
 
Generation of DR6-deficient Mice.
 
To create DR6-defi-
cient mice, a gene-targeting vector was constructed such
that homologous recombination would delete the entire
extracellular and transmembrane domain of the endoge-
nous mouse DR6 gene. The 3.9-kb deletion included ex-
ons 2 and 3, resulting in a mutant DR6 allele lacking
amino acid residues Q33 to G415 (Fig. 2 A). Three tar-
geted ES cell lines were injected into C57BL/6 blasto-
cysts. Founder mice with germline transmission were in-
terbred to produce homozygous DR6-deficient mice,
which were born at the expected Mendelian ratio. Inacti-
vation of the DR6 gene locus was verified by Southern
blot analysis (Fig. 2 B) and loss of gene expression was
demonstrated by RT-PCR analysis of total liver RNA
(Fig. 2 C). DR6-deficient mice were viable, fertile, and
Figure 1. Amino acid sequence and tissue distribution of DR6. (A) Amino acid sequence of mouse and human DR6. (B) Northern blot analysis of hu-
man DR6. Human multiple tissue Northern blots (CLONTECH) were probed with a cDNA fragment corresponding to the cytoplasmic domain of
DR6. (C) Expression of mouse DR6 in T cells. Expression of DR6 mRNA in undifferentiated T cells (Th0) or T cells differentiated for 3 d into Th1 or
Th2 cells. DR6 mRNA levels were determined by Taqman™ real-time quantitative PCR and normalized to rpl19, a ribosomal housekeeping gene. 
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detailed histological analysis did not reveal any obvious
abnormalities (data not shown).
 
Lymphocyte Populations in DR6-deficient Mice.
 
Initial
profiling of immune cells revealed a slight, though statisti-
cally significant (
 
P
 
   
 
0.05) increase in the percentage of
CD3
 
 
 
 T cells in the thymus and PBL compartments of the
knockout mice (Fig. 3 A). We further measured thymic
weight and compared the total number of thymocytes in
DR6
 
 
 
/
 
 
 
 
 
mice to control wild-type littermates. There was
no significant change in the size of the thymus or in the
number of thymocytes (data not shown). Additional analy-
sis showed that both CD4
 
 
 
 and CD8
 
 
 
 T cells were almost
elevated twofold in the PBL compartment (Fig. 3 B and
C). Flow cytometry analysis of cells stained with mAbs to
B220, Gr.1, NK1.1, F4/80, and CD14 did not indicate any
 
gross differences in B cells, neutrophils, NK cells, or mono-
cyte/macrophages in lymphoid organs of DR6-deficient
mice when compared with age- and sex-matched controls
(data not shown).
 
In Vitro T Cell Responses.
 
Given the significant in-
crease in T cell numbers in DR6-deficient mice, this
phenotype was further characterized by measuring their
proliferative capacity. Purified CD4
 
 
 
 T cells from DR6-
deficient and control wild-type littermates were stimulated
with Con A, a polyclonal T cell stimulator or with 
 
 
 
-CD3
mAb alone or 
 
 
 
-CD3 plus 
 
 
 
-CD28. Subsequently, prolif-
erative response and IL-2 production were measured. T
cells from DR6-deficient mice hyperproliferated and pro-
duced increased amounts of IL-2 as compared with wild-
type cells regardless of the nature of the proliferative stim-
Figure 2. Targeting of the DR6 gene by homologous recombination. (A) Structure of
the mouse DR6 gene and gene targeting vector. Exons 2 and 3 corresponding to the ex-
tracelluar and transmembrane regions of mDR6 were replaced by a neomycin resistance
gene under the control of the PGK promoter. B, BamHI; S, SacI; Sp, SpeI. (B) Southern
blot analysis. Genomic DNA digested with Sac I was hybridized with a [32P]-labeled probe
derived from sequence 5  to the targeting vector. (C) RT-PCR analysis of total RNA iso-
lated from livers of DR6 null and wild-type mice. PCR products representing DR6 and
GAPDH are shown in the top and bottom panel, respectively. ctl, no RNA control.
Figure 3. Effect of DR6 on T cell development. To-
tal T cells and CD8  T subpopulations were determined
in thymus (Thy), blood (PBL), spleen (Sp), and LNs
from DR6 knockout (black bars) and wild-type (white
bars) mice. Organ-specific (A) total CD3  T cells, (B)
CD4  cells, and (C) CD8  cells. Lymphoid organs
were harvested from mice and single cell suspensions
stained with mAbs and analyzed by flow cytometry. 
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ulus (Fig. 4). These data indicated that CD4
 
 
 
 
 
T cells lack-
ing DR6 were intrinsically hyperresponsive to mitogenic,
TCR, and costimulatory signals consistent with the notion
that DR6 normally functions to suppress T cell activation
and cytokine production.
In Vivo T Cell Responses. To determine the influence
of DR6 on in vivo T cell responses, wild-type and DR6-
deficient mice were immunized with KLH and 9 d later
draining LNs (DLNs) were harvested. After in vitro stimu-
lation of DLN cells with KLH, cytokine production and
recall proliferative ability of these cells was assessed. T cells
from primed DR6-deficient mice had increased prolifera-
tive responses with production of higher levels of IL-2 and
IFN-  (Fig. 5 A–C). Additionally, production of IL-4 was
markedly enhanced in DLN cells from DR6-deficient
mice, levels being almost twofold higher (Fig. 5 D). These
results indicate that DR6-deficient mice are hyperrespon-
sive to in vivo antigenic challenge. This is consistent with
our in vitro data reinforcing the notion that DR6 functions
to suppress T cell responsiveness in vivo. Although T cells
from DR6-deficient mice produced somewhat increased
levels of various cytokines, the level of IL-4 was signifi-
cantly elevated, underscoring a role for DR6 in the Th2
response. The in vivo KLH/CFA challenge experiments
were designed to examine the influence of antigenic chal-
lenge on general T cell responses and not Th differentiation
which typically requires immunization with KLH in alum.
However, even under these sub-optimal conditions, we
did see some preference for Th2 differentiation.
In Vivo Humoral Responses. Since Th2 cells regulate
humoral immunity and Ig production, particularly IgG1
and IgE antibodies while the Th1 response contributes to
the production of IgG2a and, to a lesser extent, IgG3 anti-
bodies, serum Ig levels were determined in DR6-deficient
mice. Naive DR6-deficient mice had Ig levels comparable
to wild-type littermates (Fig. 6 A). However, upon in vivo
challenge with TNP-conjugated KLH, DR6-deficient
mice developed markedly increased titers of TNP-specific
IgG1 and IgE (Fig. 6 B), whereas levels of IgM and IgG2a
were only slightly elevated. The levels of IgG1 were in-
creased by  200% in DR6-deficient mice, consistent with
preferential Th2 cell differentiation and hyperproliferation.
This marked polarization toward a Th2 response was also
substantiated by the significant increase in IL-4 production
in KLH-primed DR6    T cells (Fig. 5 D).
Figure 4. In vitro activation of T cells. For in vitro responses of T cells,
purified CD4  T cells from DR6 /  mice (black squares) or wild-type lit-
termates (black circles) were cultured in the presence of different concen-
trations of ConA or anti-CD3 alone or in the presence of anti-CD28 and
proliferation measured by 3[H]thymidine incorporation. IL-2 levels were
determined by ELISA. (A) ConA induced proliferation and (B) IL-2 pro-
duction, (C) anti-CD3 induced proliferation, and (D) IL-2 production, (E)
anti-CD3 plus anti-CD28–induced proliferation, and (F) IL-2 production.
Figure 5. Antigen-induced in vivo responses in DR6-deficient mice.
Cytokine production and proliferative response of lymph node cells from
wild-type (white circles) and DR6-deficient (white squares) mice immu-
nized with KLH in CFA. Lymph node cells were collected 9 d after im-
munization, cultured in the presence of KLH, and analyzed for their capac-
ity to proliferate (A) or produce IL-2 (B), IFN-  (C), and IL-4 (D). Data is
presented as the mean SD values derived from five animals in each group.1446 Impaired T Cell Differentiation in Death Receptor 6–deficient Mice
In Vitro Differentiation of T Cells. Since DR6-deficient
mice exhibited an enhanced Th2 response in vivo, we in-
vestigated the role of DR6 in mediating Th differentiation
in vitro. Purified naive CD4  T cells from wild-type and
DR6-deficient mice were differentiated into either Th1
cells by activating them with  -CD3 plus  -CD28 in the
presence of antibodies to IL-12 and IL-4 or into Th2 cells
in the presence of IL-4 and antibody to IFN- . When dif-
ferentiated into Th1 cells, DR6-deficient lymphocytes pro-
duced levels of IFN-  equivalent to wild-type controls (Fig.
7). In contrast, DR6-deficient lymphocytes grown in the
presence of IL-4 and anti–IFN-  produced markedly en-
hanced Th2 cytokines such as IL-4 itself. Cytokine produc-
tion was also determined by staining the T cells for intracel-
lular IFN-  and IL-4. A significantly higher number of T
cells produced IL-4 (data not shown), indicating that the IL-4
producing T cells pool was expanded in DR6 /  mice.
Taken together, our results indicate that DR6 plays a major
role in Th cell differentiation both in vivo and in vitro.
DR6 Does Not Regulate T Cell Differentiation through
Apoptosis. Since DR6 possesses an intracellular DD, this
raised the possibility that it may regulate T cell activation
and differentiation by modulating apoptosis. To address
this, AICD of thymocytes and splenic T cells from DR6-
deficient mice was measured in response to various apop-
totic stimuli. No appreciable difference was observed in
susceptibility of splenocytes or thymocytes to AICD or
death induced by other proapoptotic stimuli (Fig. 8 A and
B). Therefore, it was unlikely that decreased apoptosis ac-
counts for the increased proliferative potential of DR6-
deficient T cells. In sum, our data are consistent with an in-
trinsic, cell autonomous growth inhibitory role for DR6,
removal of which, as in the knockout cells leads to a hyper-
proliferative response.
DR6 Regulates Differentiation of T Cells by Activation of the
JNK Pathway. Given the role of the JNK-1 pathway in
Th cell differentiation and the polarized Th2 response ob-
served in both JNK-1(12) and DR6 null mice (this study),
we asked if JNK activity was correspondingly reduced in
DR6-deficient T cells. Purified CD4  T cells from wild-
type or DR6-deficient mice were stimulated with  -CD3
plus  -CD-28 and JNK activity measured using recombi-
nant c-Jun as substrate. In DR6-deficient T cells, JNK ac-
tivity was significantly reduced (Fig. 8 C), consistent with
the notion that attenuation of this MAP kinase contributes
to the polarized Th cell differentiation observed in JNK-
deficient mice (12).
Discussion
A significant role for effector Th1 and Th2 cells in
adaptive immunity has been well recognized in recent
years. Although considerable progress has been made in
defining the rules for differentiation of naive CD4  T cells
into Th1 and Th2 cells, a complete understanding of the
molecules that regulate this process has remained elusive.
Figure 6. Effect of DR6 on Ig subclasses. Serum was collected from
wild-type (black bars) and DR6-deficient mice (white bars) and subclass
concentrations determined by ELISA (A). Serum was obtained from
wild-type and DR6-deficient mice immunized with TNP-KLH in CFA
and levels of IgM, IgG1, IgE, and IgG2a determined by TNP-specific
ELISA (B). Data is presented as the mean SD values derived from five an-
imals in each group.
Figure 7. In vitro induction of Th cell differentiation and effect of
DR6 on cell death. T cells purified from spleens of wild-type (black bars)
or DR6-deficient (white bars) mice were differentiated into Th1 or Th2
cells with anti-CD3 plus anti-CD28. Production of IFN-  and IL-4 was
determined by ELISA. Data represent the mean SD of pools of five mice
per group. ND, not detected.1447 Zhao et al.
In this study, we demonstrate the role of a recently identi-
fied novel DD-containing TNFR family member, DR6,
in controlling the activation and differentiation of Th cells.
The differentiation of Th cells is influenced by a number
of factors including cytokine environment, antigen dose,
and costimulatory signals. The exact mechanism by which
such disparate factors influence Th differentiation is un-
known except that JNK, a MAPK that phosphorylates
c-Jun and enhances AP-1 transcriptional activity, is an in-
tegral component of the final common pathway. Activa-
tion of JNK in T cells requires engagement of both the T
cell receptor and costimulatory receptors such as CD28.
Our work suggests that DR6 also provides costimulatory
support for activation of the JNK pathway in T cells. The
most compelling evidence for this comes from the obser-
vation that the enhanced Th2 response seen in JNK null T
cells is also found in DR6 /  T cells. Furthermore, the in-
duction of JNK activity upon stimulation with  -CD3
and  -CD28 is substantially attenuated in CD4  T cells
from DR6-deficient mice.
The current model for differentiation of CD4  T cells
into Th1 and Th2 cells suggests that the cytokine microen-
vironment plays a crucial role (4, 22, 23). The most critical
cytokine for Th1 development is IL-12 as mice deficient in
IL-12, IL-12 receptor  1, or the associated signaling mole-
cule Stat4 possess markedly reduced Th1 responses (24).
Conversely, IL-4, acting via Stat6, is the primary inducer of
Th2 development (25), as mice deficient in either IL-4, IL-4
receptor, or the associated downstream signaling adaptor
Stat6 do not develop Th2 responses. Besides promoting
growth and differentiation of their own subset Th1 and
Th2 cytokines also cross-regulate by inhibiting the devel-
opment of the opposing subset. For example, IL-4 down-
regulates IL-12 receptor expression on developing Th cells,
thereby committing them to a Th2 lineage (26, 27). Simi-
larly, IFN-  promotes Th1 development by inducing IL-
12 and inhibiting Th2 cell growth (26, 28, 29). This study
suggests an exception to the current model of Th cell dif-
ferentiation, as DR6-deficient mice possess an enhanced
Th2 response but normal Th1-associated responses. There-
fore, it appears that in this particular instance Th2 type cy-
tokines are not counterregulating the Th1 response. The
exact mechanism for this is unclear but probably has to do
with the nature of the signaling pathways engaged by DR6.
Although DR6 is a DD-containing receptor, it appears not
to mediate apoptosis but rather activation of the JNK path-
way. To a much lesser extent, DR6 also activates the nu-
clear factor  B pathway, but it is difficult to assess whether
this is of physiological significance. The precise signaling
pathway used by DR6 to activate the JNK pathway awaits
definition. Since known DD signaling adapters such as
TRADD and FADD do not associate with DR6, it is likely
that a yet to be elucidated intermediary adaptor(s) provide
the physical link between DR6 and JNK. Besides identifi-
cation of components of the DR6 signaling complex, an
equally important question is the nature of the ligand for
DR6. It is tempting to speculate that activated T cells are
the autocrine source of the ligand since the substantial dif-
ference in JNK activity seen between wild-type and DR6
knockout CD4  T cell cells (Fig. 8 C) is observed with a
purified CD4  T cell population that lacks contaminating
APCs. Identification of the ligand may have potential ther-
apeutic value as our work suggests that activating the DR6
pathway will suppress the evolution of a Th2 response and
may therefore represent a novel strategy to treat Th2-
mediated diseases such as chronic asthma.
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Figure 8. Effects of DR6 on thymocyte apoptosis. (A) Apoptosis was
induced in thymocytes from wild-type (black bars) and DR6-deficient
(white bars) mice with soluble FLAG-tagged FasL and  -FLAG antibody,
plate-bound  -CD3 plus  -CD28, etoposide, and dexamethasone. Per-
centage of surviving cells were analyzed using PI/FITC-annexin V stain-
ing of cells by flow cytometry 24 h after treatment. (B) Effects of DR6 on
AICD. Splenocytes from wild-type and DR6-deficient mice were acti-
vated with Con A for 2 d, followed by culture in medium containing
murine recombinant IL-2 for 2 d. The activated lymphocytes depleted of
dead cells were treated with either soluble FLAG-tagged FasL and  -FLAG
antibody or plate-bound  -CD3 for 24 h. Percentage of surviving cells
were analyzed by PI/FITC-annexin V staining by flow cytometry 24 h af-
ter treatment. Abrogation of JNK activation in DR6-deficient CD4  T
cells (c) Purified splenic CD4  T cells from wild-type (WT) or DR6-
deficient (KO) mice were stimulated with anti-CD3 and anti-CD28 for
48 h. JNK activity was measured using GST-Jun as substrate. Expression
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